共 9 条
[1]
McDonagh T.A., Et al., ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, Eur Heart J. 2021, 42, pp. 3599-3726, (2021)
[2]
McDonagh T.A., Et al., Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, Eur Heart J., (2023)
[3]
Soltani S., Et al., Frühe Implementierung der „Fantastic four“ bei Herzinsuffizienz mit reduzierter EjektionsfraktionLeitliniengerechte medikamentöse Therapie - Ein praktischer Leitfaden, DMW, 147, pp. 931-938, (2022)
[4]
Abdin A., Et al., A practical approach to the guideline-directed pharmacological treatment of heart failure with reduced ejection fraction, ESC Heart Fail, 10, pp. 24-31, (2023)
[5]
Zannad F., Et al., SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials, Lancet, 396, pp. 819-829, (2020)
[6]
Docherty K.F., Et al., Effects of dapagliflozin in DAPA-HF according to background heart failure therapy, Eur Heart J, 41, pp. 2379-2392, (2020)
[7]
Shen L., Et al., Dapagliflozin in HFrEF patients treated with mineralocorticoid receptor antagonists: An analysis of DAPA-HF, JACC Heart Fail, 9, pp. 254-264, (2021)
[8]
Desai A.S., Et al., Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril/valsartan compared with enalapril: A secondary analysis of the approach to treatment of heart failure PARADIGM-HF trial, JAMA Cardiol, 2, pp. 79-85, (2017)
[9]
Maximilian W., Schwinger R.H.G., Repetitive Therapie mit Levosimendan reduziert NT-proBNP und verbessert NYHA-Klasse: Ein Fallbericht, Aktuelle Kardiologie, 11, pp. 484-489, (2022)